Spots Global Cancer Trial Database for Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy Adherence

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy Adherence

Official Title: Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy Adherence

Study ID: NCT04663100

Conditions

Chronic Myeloid Leukemia

Chronic Lymphocytic Leukemia

Multiple Myeloma

Multiple Chronic Conditions

Interventions

Patient-reported outcome measure

Comprehensive Medication Review

Pharmacist communication

Study Description

Brief Summary: The objective of this study is to improve medication, symptom, and disease management of patients with hematological malignancies and multiple chronic conditions (2 or more conditions in addition to cancer) through care coordination between pharmacists working in oncology practices and those working in primary care or community practices (Pharmacists Coordinated care Oncology Model \[PCOM\]). This is a pilot study in which the investigators will examine the association between outcome measures, but the study design and sample size are insufficient to quantify the impact of OAA initiation or OAA adherence on adherence to chronic medications. This pilot study and data analyses are being done in preparation for a larger, controlled study.

Detailed Description: